Structural Insight into the Resistance of the SARS-CoV-2 Omicron BA.4 and BA.5 Variants to Cilgavimab

We have recently revealed that the new SARS-CoV-2 Omicron sublineages BA.4 and BA.5 exhibit increased resistance to cilgavimab, a therapeutic monoclonal antibody, and the resistance to cilgavimab is attributed to the spike L452R substitution. However, it remains unclear how the spike L452R substitut...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Shigeru, Kosugi, Yusuke, Kimura, Izumi, Yamasoba, Daichi, Sato, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785715/
https://www.ncbi.nlm.nih.gov/pubmed/36560681
http://dx.doi.org/10.3390/v14122677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785715/
https://www.ncbi.nlm.nih.gov/pubmed/36560681
http://dx.doi.org/10.3390/v14122677

Ejemplares similares